Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CCR3 | P51677 | 9/20 | 0.52 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.48 |
| ▸ | ITGAL | P20701 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8014171 | 0.87 | CCR3 (0.66) | CA2CCR3ITGB2ICAM1ITGAL | |
| SCHEMBL7608481 | 0.87 | CCR3 (0.66) | CA2CCR3ITGB2ICAM1ITGAL | |
| SCHEMBL25191174 | 0.83 | ITGB3 (0.53) | CA2CCR3ITGB2ICAM1ITGAL | |
| SCHEMBL25191171 | 0.83 | ITGB3 (0.53) | CA2CCR3ITGB2ICAM1ITGAL | |
| SCHEMBL30035222 | 0.80 | CA2 (0.60) | CA2CCR3ITGB2ICAM1ITGAL | |
| SCHEMBL8017638 | 0.79 | CCR3 (0.58) | CCR3NPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL3935453 | 0.78 | CCR3 (0.67) | CCR3ELANENPC1TP53RAB9A | |
| SCHEMBL3935460 | 0.78 | CCR3 (0.67) | CCR3ELANENPC1TP53RAB9A | |
| SCHEMBL3930225 | 0.78 | CCR3 (0.62) | CCR3ELANE | |
| SCHEMBL3930227 | 0.78 | CCR3 (0.62) | CCR3ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592482-B2 | CCR3 inhibition for ocular angiogenesis and macular degeneration | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2013-11-26 | — | — | US | claimed |
| US-20110268723-A1 | CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-11-03 | — | — | US | claimed |
| US-20090123375-A1 | CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2009-05-14 | — | — | US | claimed |
| WO-2007098113-A2 | CCR3 INHIBITION FOR OCULAR ANGIOGENESIS AND MACULAR DEGENERATION | UNIVERSITY OF KENTUCKY (US) | 2007-08-30 | — | — | WO | claimed |
| US-20240191238-A1 | BIOMARKERS OF AGING FOR DETECTION AND TREATMENT OF DISORDERS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-06-13 | — | — | US | disclosed |
| US-11912998-B2 | Method of treating aging-associated cognitive impairment by reducing CCR3 | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220213487-A1 | CCR3 MODULATION IN THE TREATMENT OF AGING-ASSOCIATED IMPAIRMENTS, AND COMPOSITIONS FOR PRACTICING THE SAME | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-07-07 | — | — | US | disclosed |
| US-11345756-B2 | CCR3 inhibition for ocular angiogenesis and macular degeneration | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2022-05-31 | — | — | US | disclosed |
| US-11236340-B2 | Method of reducing the effects of aging-associated impairment of neurogenesis comprising modulating c-c chemokine receptor type 3 (CCR3) | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200399644-A1 | CCR3 MODULATION IN THE TREATMENT OF AGING-ASSOCIATED IMPAIRMENTS, AND COMPOSITIONS FOR PRACTICING THE SAME | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2020-12-24 | — | — | US | disclosed |
| US-10626399-B2 | Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3) | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-04-21 | — | — | US | disclosed |
| US-20200054745-A1 | METHODS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION | LASHKARI KAMERAN (US) | 2020-02-20 | — | — | US | disclosed |
| US-20120064010-A1 | CCR3 and its Ligands Are Therapeutic and Diagnostic Targets for Neovascular Age-Related Macular Degeneration | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110268723-A1 | CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-11-03 | — | — | US | disclosed |
| US-8008092-B2 | CCR3 inhibition for ocular angiogenesis and macular degeneration | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-08-30 | — | — | US | disclosed |
| WO-2010138591-A1 | CCR3 AND ITS LIGANDS ARE THERAPEUTIC AND DIAGNOSTIC TARGETS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010129351-A1 | METHOD TO IDENTIFY AND TREAT AGE-RELATED MACULAR DEGENERATION | SCHEPENS EYE RESEARCH INSTITUTE (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20090123375-A1 | CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2007098113-A2 | CCR3 INHIBITION FOR OCULAR ANGIOGENESIS AND MACULAR DEGENERATION | UNIVERSITY OF KENTUCKY (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070190055-A1 | CCR3 inhibition for ocular angiogenesis and macular degeneration | KENTUCKY RESEARCH FOUNDATION, UNIVERSITY OF | 2007-08-16 | — | — | US | disclosed |